Under one in 10 individuals who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it issues its first guidance on the drugs.
With more than one billion individuals worldwide currently obese, it is urging increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key hurdles to broad access to the jabs that can assist patients in reducing significant weight, explains the organization.
GLP-1 Therapy Supply Crisis
Even in the present best projected scenario, the manufacturing of such drugs might only reach about 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice encourages nations and manufacturers to expand availability, by approaches such as voluntary licensing.
Exclusive production rights on a key compound – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Function
These medications mimick a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so individuals consume fewer calories.
People commonly see weight reduction after several weeks of starting on the regular doses.
Studies indicates users may see weight return a year later of stopping the drug, when their typical food cravings resume.
Being carrying excess weight raises your likelihood for experiencing health problems, such as diabetes, heart disease, stroke, and some cancers.
Obesity affects individuals in every country and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
